Biocon has entered into a $350-million (Rs 1,550 crore) strategic alliance with drug-major Pfizer on marketing Biocon’s insulin products. The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insulin, glargine, aspart and lispro,.
Under the terms of the agreement, Pfizer will make upfront payments of $200 million. Biocon is also eligible to receive an additional development and regulatory milestone payment of up to $150 million. In addition to the $350 million, the company will also receive additional payments linked to Pfizer’s sales of its four insulin biosimilar products across global markets. The company will launch recombinant human insulin in emerging markets in the first phase and then introduce it in Europe in 2012 with the timeline for introduction in the
The potential market for these four products, according to Kiran Mazumdar Shaw , chairman and MD of Biocon, would roughly be around $20 billion by 2015. Biocon hopes to combine the synergies of Pfizer’s marketing and distribution networks and its own cost-effective developing and manufacturing capabilities to grab a piece of the $14-billion biosimilar market.
crackcrackCompany Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |